Rituximab for idiopathic membranous nephropathy

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Idiopathic membranous nephropathy (IMN) is a leading cause of nephrotic syndrome.
• Current treatments for IMN carry significant toxicity risks.
• B cells play a crucial role in the pathogenesis of IMN.

Purpose of the Study:

• To evaluate the efficacy and safety of rituximab in treating persistent idiopathic membranous nephropathy.
• To assess the impact of rituximab on proteinuria, albuminuria, and serum albumin levels.

Main Methods:

• Eight patients with IMN and persistent nephrotic syndrome received four weekly infusions of rituximab (375 mg/m²).
• Rituximab targets the CD20 B-cell antigen.
• Clinical and laboratory parameters were monitored up to study end.

Main Results:

• Significant reduction in urinary protein from 8.6 g/24h to 3.8 g/24h at week 4 and 3.7 g/24h at week 20 (p<0.0001).
• Albuminuria and albumin fractional clearance decreased by 70% and 65% respectively at week 20.
• Serum albumin increased by 31% at week 20.
• CD20 B lymphocytes decreased below normal ranges throughout the study.

Conclusions:

• Rituximab demonstrates a favorable short-term risk-benefit profile for treating IMN.
• B-cell depletion with rituximab is an effective therapeutic strategy for idiopathic membranous nephropathy.
• Further research is warranted to confirm long-term efficacy and safety.